about
A Semiparametric Regression Cure Model for Interval-Censored DataImputation for semiparametric transformation models with biased-sampling data.Empirical likelihood-based confidence intervals for length-biased dataSemiparametric Accelerated Failure Time Model for Length-biased Data with Application to Dementia StudyPractical Implications of the Publication of Consensus Guidelines by the American Society for Radiation Oncology: Accelerated Partial Breast Irradiation and the National Cancer Data Base.Permutation tests for comparing marginal survival functions with clustered failure time data.Marginal analysis of correlated failure time data with informative cluster sizes.A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.Statistical methods for analyzing right-censored length-biased data under cox model.Analyzing Length-biased Data with Semiparametric Transformation and Accelerated Failure Time Models.Buckley-James-type estimator with right-censored and length-biased data.First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.p63 expression defines a lethal subset of muscle-invasive bladder cancers.Maximum Likelihood Estimations and EM Algorithms with Length-biased Data.Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution.Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosisLikelihood approaches for the invariant density ratio model with biased-sampling data.Risk-specific optimal cancer screening schedules: an application to breast cancer early detectionEvidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery.Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status.Statin use in primary inflammatory breast cancer: a cohort study.Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer.Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experienceNeoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer.Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.Symptomatic local recurrence of prostate carcinoma after radiation therapy.A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers.Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray.High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.Increased apoptosis in metastatic human colonic adenocarcinomas.Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up.Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
P50
Q30493910-6CEE393E-BFB9-424F-9B63-10B69AD6675BQ30558225-F4B1221A-D221-4824-B7BC-6C4109D247A8Q30571614-7A8CF331-27FC-43C5-88C6-9CC7F4B15062Q30745929-566F6BF1-568B-4CA4-9B52-1CE55E198481Q31043481-418D1194-9B38-476B-B5C9-B5998C977BACQ31816725-60E2E53D-F170-4F58-9518-C033ED3CDA59Q33297915-E3388A48-27CA-4D44-8978-BFE339333FC2Q33402932-88E8DD0C-9399-431C-80AC-7D41B0738949Q33467005-F416AE28-FC8A-4299-BDF2-13A733AB15A9Q33740615-08E00B66-7BF6-4254-89EC-C783F67AAE6EQ33840006-D40C43AC-BE2F-4014-B942-D51D995F967DQ34104204-83CEEFD6-12F3-4851-BFF6-AAF3A109FA30Q34131185-1D632F30-36A8-48C4-BE02-E5FAF5C94C7CQ34155986-CFA144C5-2638-460B-83EE-25F5D81A07C6Q34182866-6966BEAE-D41D-4501-BDAA-4FFC1EE87AADQ34392877-46D33AAA-6174-42DB-A229-C7ABB1474305Q34414620-0C485295-E521-4F65-A350-B62B09D63D2CQ34478105-91BB1F20-5113-47DA-BB40-732C2E6959A7Q34811652-FEB5BD09-9549-4491-A3F4-7FBD216FF96AQ35591304-BFFC152E-8734-48E5-A433-5E84231B0758Q35833326-8C30B9DC-BCA5-4195-8831-928CBF1A42BCQ36135193-DA641F37-F47A-499C-A8D2-11B5483D0EE1Q36339415-BD1FBF2F-5238-40A2-9132-1825F2F66A23Q37040602-FFE298AC-AE19-466B-97C5-7E7ACBA09C91Q37151892-89862DBB-AD3A-4DA1-BFC5-FBC4B246B472Q37239994-824293A0-66BC-426D-8005-6E2BFE3F7F6FQ37274315-F581E002-6022-4D86-AE18-2CB48CABE1E2Q37276850-DA543B1C-DFF0-4FE2-B23B-BB7F96A5B31EQ38387200-4CB48BCA-6615-40B6-AB71-A2F20D61ACAFQ38449382-B9C67BC0-0864-449F-B75B-DCC92277A3E9Q40431547-F7C4C191-DA8F-44E4-A7C7-CFE5CA6E2332Q41092995-BB576F3C-F0AA-4151-A2AE-8CD67A69AF50Q42089905-8DCE77F5-2F0B-4BEA-88B9-89C9B42C60D0Q43763239-78048FF5-7FE3-4873-9229-6606A05129AEQ44096690-C347414D-E9BF-4EC1-BAC3-28EF897C326CQ45704455-AD110BD0-2BAB-425A-B678-D27B4EF1EA31Q46474294-F9CFCE24-0EF0-4186-ACC5-6263C688A333Q47252800-A00C65A7-7F9E-4F75-ABA2-A4FF4CB41390Q47397727-F0967009-4DA2-4BEF-8587-E1D5B94F53ECQ47688431-6326620A-51F7-4F2E-862C-C898F9D48596
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yu Shen
@ast
Yu Shen
@en
Yu Shen
@es
Yu Shen
@nl
Yu Shen
@sl
type
label
Yu Shen
@ast
Yu Shen
@en
Yu Shen
@es
Yu Shen
@nl
Yu Shen
@sl
prefLabel
Yu Shen
@ast
Yu Shen
@en
Yu Shen
@es
Yu Shen
@nl
Yu Shen
@sl
P214
P106
P1153
7404766770
P214
P31
P496
0000-0002-3899-7868
P7859
lccn-nr95011672